Biosignal: Collaboration with international company on agriculture applications
Evaluation for use in crop protection to be conducted over 9 months
Biosignal Limited has signed an agreement with a leading international agrichemicals company to evaluate its unique antimicrobial technology for use in crop and seed protection. The evaluation will be conducted at the facilities of, and fully funded by the partner company.
Biosignal's compounds are primarily in demand for their unique activity against bacterial biofilms, however in trials at Biosignal the compounds have also demonstrated a high level of activity against fungi. Fungal and bacterial pathogens cause significant damage to field crops, and result in the spoiling of seeds in storage and in the ground prior to germination. The agricultural sector is actively seeking novel and environmentally friendly treatments to combat these problems.
"Strategically, Biosignal is targeting the application of its technology in five key areas; industrial, agricultural, consumer, therapeutics and medical devices. These areas are ultimately anticipated to be separate business units or entities, and this deal is a positive early step in our strategy to establish a dedicated agricultural business," said Professor Peter Steinberg, CEO of Biosignal. 'We anticipate further developments in this field over the course of the year".
The evaluation will be conducted over the next 9 months with results expected early in 2009. The agreement is non-exclusive.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Modified_starch
Indivumed to study the integrity of biospecimen sampling procedures for the U.S. National Cancer Institute - Analysis of biopsy sampling procedures a prerequisite for the development of future individualized cancer therapies

Surfers three times more likely to have antibiotic-resistant bacteria in guts
HNCOCA_experiment
Evotec completes acquisition of Just Biotherapeutics
Eicosapentaenoic_acid
Symbiosis_Institute_of_Geoinformatics
